{"nctId":"NCT01910116","briefTitle":"Efficacy of Shinabro in Hand Osteoarthritis","startDateStruct":{"date":"2013-09"},"conditions":["Hand Osteoarthritis"],"count":220,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Shinbaro","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Shinbaro"]}],"interventions":[{"name":"Shinbaro","otherNames":["GCSB-5"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age of 40 years or older\n* Osteoarthritis according to ACR 1990 criteria\n* Mean joint visual analog pain score (VAS) \\> 30mm in the preceding 48 hours\n* Patients who are will to participate\n\nExclusion Criteria:\n\n* Any prior surgery of hand joints\n* prior history of Shinbaro use\n* Intra-articular injection of glucocorticosteroid or hyaluronic acid in the preceding 3 months\n* Pregnancy or active breast feeding\n* Prior hypersensitivity reaction to herbal medications\n* AST or ALT elevation \\> 3 of upper normal limit\n* GRF (MDRD) \\< 30 mg/min/1.73m2\n* Nephrotic syndrome, other signficant kidney disease\n* Patients who seem not to tolerate the study at investigator's discretion\n* Patients who refuse to participate","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"AUSCAN Pain Change at 4 Weeks From Baseline","description":"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).\n\nAUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":null},{"groupId":"OG001","value":"-2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Pain Score at 8 Weeks From Baseline","description":"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":null},{"groupId":"OG001","value":"-2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Pain Score at 12 Weeks From Baseline","description":"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.6","spread":null},{"groupId":"OG001","value":"-8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Pain Score at 16 Weeks From Baseline","description":"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.6","spread":null},{"groupId":"OG001","value":"-4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Stiffness at 4 Weeks Change From Baseline","description":"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":null},{"groupId":"OG001","value":"-6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Stiffness at 8 Weeks Change From Baseline","description":"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.0","spread":null},{"groupId":"OG001","value":"-6","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Stiffness at 12 Weeks Change From Baseline","description":"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":null},{"groupId":"OG001","value":"-11.0","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Stiffness at 16 Weeks Change From Baseline","description":"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":null},{"groupId":"OG001","value":"-8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Function Change at 4 Weeks From Baseline","description":"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":null},{"groupId":"OG001","value":"-3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Function Change at 8 Weeks From Baseline","description":"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":null},{"groupId":"OG001","value":"-4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Function Change at 12 Weeks From Baseline","description":"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11","spread":null},{"groupId":"OG001","value":"-2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"AUSCAN Function Change at 16 Weeks From Baseline","description":"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":null},{"groupId":"OG001","value":"-4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Assessment, Change From Baseline","description":"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":null},{"groupId":"OG001","value":"-3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Assessment, Change From Baseline","description":"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":null},{"groupId":"OG001","value":"-6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Assessment, Change From Baseline","description":"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.0","spread":null},{"groupId":"OG001","value":"-6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Assessment, Change From Baseline","description":"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":null},{"groupId":"OG001","value":"-8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician Global Assessment, Change From Baseline","description":"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12","spread":null},{"groupId":"OG001","value":"-7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician Global Assessment, Change From Baseline","description":"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":null},{"groupId":"OG001","value":"-11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician Global Assessment, Change From Baseline","description":"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":null},{"groupId":"OG001","value":"-13","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician Global Assessment, Change From Baseline","description":"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12","spread":null},{"groupId":"OG001","value":"-6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Tender Joint Count, Change From Baseline","description":"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Tender Joint Count, Change From Baseline","description":"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Tender Joint Count, Change From Baseline","description":"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Tender Joint Count, Change From Baseline","description":"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Swollen Joint Count, Change From Baseline","description":"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Swollen Joint Count, Change From Baseline","description":"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Swollen Joint Count, Change From Baseline","description":"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Swollen Joint Count, Change From Baseline","description":"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..\n\n* Negative value means improvement from baseline\n* Positive value means deterioration from baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Acetaminophen Rescue","description":"yes = AAP rescue use, no = no AAP rescue use","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Acetaminophen Rescue","description":"yes = AAP rescue use, no = no AAP rescue use","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Acetaminophen Rescue","description":"yes = AAP rescue use, no = no AAP rescue use","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Acetaminophen Rescue","description":"yes = AAP rescue use, no = no AAP rescue use","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of OMERACT-OARSI Responder","description":"Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of OMERACT-OARSI Responder","description":"Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of OMERACT-OARSI Responder","description":"Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of OMERACT-OARSI Responder","description":"Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":109},"commonTop":["Abdominal discomfort","Skin rash","Upper respiratory infection","Nausea","Leukopenia"]}}}